WASHINGTON, DC – The Association for Accessible Medicines and the Biosimilars Council today released the following statement from President and CEO John Murphy III on the 2024 Presidential and Congressional elections.
“We congratulate President-Elect Donald Trump and the newly elected and re-elected Members of Congress. AAM and the Biosimilars Council as always looks forward to working with Congress, regulators, and the White House on real solutions to help patients increase access to generic and biosimilar medicines and solidify a sustainable and robust generic marketplace that is currently under threat. There is bipartisan consensus on the need to support a robust and resilient generic and biosimilar market in the US, which supplies 90% of all prescribed drugs but only represents 13% of the spending and is the only element of the healthcare ecosystem where prices decrease. However, much needs to be done to sustain this important market and to ensure that patients themselves actually benefit from the price competition generic products bring to the market. AAM and our membership will continue to work with all stakeholders to pursue solutions that expand the market and benefit patients this year and in the coming years.”
